,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'destiny04', 'breast']
standing ovation @ plenary session on the much awaited #destiny04 by dr. modi - t-dxd establishes new standard of care in her-2 low metastatic breast cancer both hr(+)and (-) #asco22 #mbc also published in today 
GU Oncology Fellow | NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | #ASCO22 Featured Voice | COI: https://t.co/X1Y9QuHs6L